University of Miami: Lymphoma trials

The registry lists 13 Lymphoma studies with University of Miami as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 2 7Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Precise Oncology Interventions in Nutrition and Training (OnPoint)RecruitingNCT06534918Not applicable
• Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareRecruitingNCT05745285Not applicable
• Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminatedNCT04189952Phase 2Results posted
• Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165CompletedNCT02507336Phase 2Results posted
• Chemotherapy for Relapsed Epstein Barr Virus Associated LymphomaTerminatedNCT01964755Phase 2Results posted
• Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/LymphomaTerminatedNCT00854581Phase 4Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZLTerminatedNCT00772668Not applicableResults posted
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone LymphomaCompletedNCT00453102Phase 2Results posted
• R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaCompletedNCT00450801Phase 2Results posted
• Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)TerminatedNCT00450385Phase 2Results posted
• Assessing the Effectiveness of Individual Education Plans for Childhood Cancer SurvivorsCompletedNCT00945828Not applicable
• Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to TreatmentWithdrawnNCT00881387Phase 2
• Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin LymphomaWithdrawnNCT00513188Not applicable